3. Expand Distribution – VISX joins forces with Allergan Surgical
VISX makes a formal offer to acquire Allergan’s Surgical division several years before it is spun out as AMO. Given the pressure from activist investor Carl Icahn, management is replaced and led by longtime Allergan executive Jim Mazzo, who is appointed CEO.
This merger/acquisition would have brought together VISX’s specialized refractive laser and business development team with Allergan Surgical’s cataract division (phaco and IOL), with the majority of customers doing both refractive and cataract procedures. An added boost from Allergan’s Amadeus Microkeratome would have helped complete the package.
The mechanics of this deal matter as much as the logic behind it. Rather than being acquired by AMO in 2005, VISX becomes the acquirer—years earlier, and from a position of financial strength rather than the diminished one it actually occupied by the time the roles reversed. A VISX-led combination would likely have entered the 2008 downturn better capitalized than the AMO entity that actually existed, giving the company more room to weather a recession that hit elective, cash-pay procedures especially hard.
The distribution math alone made the case. VISX’s small, focused sales team of roughly 18 people would have been joined by Allergan Surgical’s much larger force of approximately 110 reps already calling on the cataract side of the same practices. Since most refractive surgery customers were also performing cataract procedures, the combined company would not have needed to build new relationships—it would have needed only to sell more broadly and more often into relationships it or its new partner already had. That is the kind of distribution leverage that reshapes a company’s addressable market without reshaping its cost structure.
At scale, this combination would have put VISX in a different competitive class entirely—closer to Alcon, Bausch & Lomb, and Zeiss in ophthalmic device footprint than to a single-category laser company. And because cataract surgery was, and remains, the most widely performed surgical procedure in the world, a combined VISX-Allergan Surgical entity would have given ophthalmology a foothold at the top of both the reimbursed and the elective surgical categories simultaneously—a position no other device company in the specialty has held before or since.
Lessons for the Entrepreneurial CEO
VISX is an exceptional case study not because the company was uniquely reckless, but because it was uniquely positioned to succeed and still found a way to stumble. The resources were there. The market was there. The customer loyalty was there… until it wasn’t. What the story offers every entrepreneurial CEO is a set of principles that are as applicable to today’s rising stars in ophthalmology as they were to VISX in 1999.
Don’t Betray Your Customers’ Loyalty
Customer loyalty is the most valuable asset on a balance sheet that never appears there. VISX built extraordinary goodwill over five years through product quality, field service commitment, and a business model that made customers feel like partners rather than distributors. The decision to fund a discount chain that competed directly with those same customers did not just damage a few relationships. It destroyed the foundation of trust that everything else was built on. The lesson is simple, and it is ruthless: your customers’ loyalty is not a renewable resource. Treat it accordingly.
Invest in the Future—Especially When You Have the Resources to Go Shopping
VISX spent nearly $300 million buying back its own stock during the years when it could have been acquiring IntraLase, building a next-generation laser platform, or expanding into cataract surgery through Allergan Surgical. Stock buybacks improve earnings per share in the short term and signal to analysts that management has run out of ideas for how to grow. The companies that define industries over decades are the ones that reinvest aggressively when they have the balance sheet to do so. VISX had that balance sheet. It chose not to use it.
Avoid NIH, the “Not Invented Here” Syndrome
IntraLase was not invented at VISX. That may be precisely why VISX did not pursue it. The femtosecond laser represented a fundamentally better approach to flap creation, and it was available. The willingness to acquire, integrate, and champion technology that did not originate internally is one of the clearest markers of a mature and confident leadership team. Its absence is equally telling.
Get Outside Counsel on Pricing Strategy
The decision to cut the per-procedure fee by 60% was made without apparent input from economists, consumer behavior researchers, or marketing scientists who understood the dynamics of cash-pay elective medicine. As noted in Part 1, medical care does not follow a classic economic price/volume curve. In lifestyle-enhancing surgery, the highest-priced provider is frequently the preferred vendor. Bringing in expert external voices on a decision of this magnitude, one that touched every customer relationship the company had, was not optional. It was essential. It did not happen.
Know Your Customers’ Customer
Every decision VISX made between 2000 and 2005 focused on the physician customer: the surgeon, the clinic, the corporate chain. What was consistently underweighted was the patient. That’s the person sitting across the consultation desk who was making an expensive decision about their eyesight based on trust, perceived quality, and social proof. Had VISX kept that patient at the center of its strategic thinking, it would have recognized that a 60% fee reduction did not make the procedure more accessible. It made it less credible. Understanding what your customers’ customers need, fear, and value is not a marketing exercise. It is a strategic imperative.
